Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...